Although further studies in primary CD34+ cells from DC patients with mutation of the CR4/CR5 will surely further demonstrate its potential use to treat neutropenia, our study with zebrafish models of PN disease31,32, strongly suggests its wide therapeutic potential in treating neutropenic congenital diseases caused by different mutations, beside those caused by mutations in TERC or telomeric proteins. This evidence concerns the gene TERC and Decreased total neutrophil count.